Vibrio Cholerae, Live Attenuated
drugOn this page
Also known as Cholera vaccineCholera vaccine live oralCholeralive attenuatedCvd hgr 103 vaccinePXVX-0200VaxchoraVibrio cholerae
Summary
Vibrio Cholerae, Live Attenuated (CHEMBL2108939) is an approved vaccine component (ATC J07AE02); indicated across 4 conditions including vibrio infectious disease and inflammatory bowel disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Vaccine component
- ATC class: J07AE02
- Indications: 4 conditions
- Clinical trials: 9
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108939 |
| Name | Vibrio Cholerae, Live Attenuated |
| Type | Vaccine component |
| Max phase | 4 |
| ATC | J07AE02 |
Also known as: Cholera vaccine, Cholera vaccine live oral, Cholera, live attenuated, Cvd hgr 103 vaccine, PXVX-0200, Vaxchora, Vibrio cholerae, VIBRIO CHOLERAE, LIVE ATTENUATED
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| vibrio infectious disease | 4 | MONDO:0007014 | EFO:1001235 |
| inflammatory bowel disease | 1 | MONDO:0005265 | EFO:0003767 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 9.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 6 |
| PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03705585 | PHASE4 | RECRUITING | CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera |
| NCT01579448 | PHASE4 | COMPLETED | Evaluation of a Boosting Regimen With Oral Cholera Vaccine |
| NCT03373669 | PHASE4 | COMPLETED | Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine |
| NCT03724357 | PHASE4 | TERMINATED | Blood Donor CVD 9000 |
| NCT05453253 | PHASE4 | UNKNOWN | Immune Response to a Delayed Second Dose of Oral Cholera Vaccine |
| NCT06104345 | PHASE4 | COMPLETED | Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines |
| NCT03581734 | PHASE3 | UNKNOWN | Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine |
| NCT03251495 | PHASE2 | COMPLETED | Immunologic Responses to a Live Attenuated Oral Cholera Vaccine |
| NCT01981616 | PHASE1 | COMPLETED | Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.